Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.95 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681206 | 1.00 | PKM (0.95) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6886844 | 1.00 | PKM (0.95) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5805656 | 1.00 | PKM (0.95) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2681204 | 1.00 | PKM (0.95) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL18543598 | 1.00 | PKM (0.95) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| Water SCHEMBL15937868 | 0.98 | PKM (0.91) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL20271907 | 0.98 | PKM (0.91) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL21490554 | 0.98 | PKM (0.91) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL566542 | 0.98 | PKM (0.91) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| Acetic Acid SCHEMBL28202990 | 0.88 | PKM (0.74) | PKMGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 986 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079849-A | Slave dimension lattice in the mother liquor of the statin method for efficiently recycling vildagliptin | — | 2026-05-26 | — | — | CN | claimed |
| CN-120131975-A | Host-guest fucoidin carrier, preparation method and application thereof, fucoidin nanocrystalline delivery system, preparation method and application thereof, pharmaceutical composition and application thereof | 石河子大学第一附属医院 | 2025-06-13 | — | — | CN | claimed |
| CN-116656296-B | High-temperature-resistant packaging adhesive for electronic components and manufacturing process thereof | 烟台固邦新材料有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-222657799-U | Distillation plant is used in production of 3-amino-1-adamantanol | 开封缘润药业有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119661318-A | Method for recycling side reaction products in production of 3-amino-1-adamantanol | 四川众邦新材料股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-116120554-B | Composition for optical lens material with high refractive index and low thermal expansion coefficient | 益丰新材料股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119391224-A | Water-based decorative paper ink and preparation method thereof | 杭州临安汇美装饰材料有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119258951-A | Purification process and equipment for vildagliptin | 华融(广东)制药有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119059954-A | Synthesis and preparation method of vildagliptin | 苏州翔实医药发展有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-119059955-A | Wigliptin Process for purifying a statin | 苏州翔实医药发展有限公司 | 2024-12-03 | — | — | CN | claimed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2005021536-A2 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | SANOFI-AVENTIS (FR) | 2005-03-10 | — | — | WO | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | PKM 3216/4885GRIN2D 412/4885GRIN3B 123/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | PKM 2611/4885GRIN2D 2313/4885GRIN3B 1391/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | PKM 1837/4885GRIN2D 539/4885GRIN3B 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.